Welcome to our dedicated page for Nuwellis SEC filings (Ticker: NUWE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
When you follow a medical-device innovator like Nuwellis, questions surface fast: Are Aquadex SmartFlow sales rising? Did insiders buy shares after new pediatric trial data? What 8-K events flagged supply-chain shifts? The answers live inside dense SEC documents, but manually sifting through each filing is costly and time-consuming.
Stock Titan solves that problem with AI-powered summaries that turn disclosure language into clear insight. Our platform streams every Nuwellis quarterly earnings report 10-Q filing and provides "Nuwellis 8-K material events explained" within minutes of hitting EDGAR. Revenue by product line, R&D spend on renal monitoring, and liquidity updates are extracted automatically, giving you an instant "Nuwellis earnings report filing analysis" without paging through footnotes. Direct links guide you to the exact lines inside a "Nuwellis annual report 10-K simplified" so you can verify numbers in context.
Need governance intelligence? Our real-time feed of "Nuwellis Form 4 insider transactions real-time" tracks every Nuwellis executive stock transactions Form 4. AI annotations flag buying or selling patterns that often precede pivotal announcements. Curious about pay packages? One click surfaces the "Nuwellis proxy statement executive compensation" tables, translated into plain-English cost-per-share metrics.
Whether you search for "Nuwellis SEC filings explained simply" or "understanding Nuwellis SEC documents with AI," this page delivers complete coverage—10-K, 10-Q, 8-K, S-1, and every "Nuwellis insider trading Form 4 transactions"—all tagged, searchable, and exportable. Save hours, spot trends, and make informed decisions with confidence.
Nuwellis has received a delisting notice from Nasdaq on June 18, 2025, due to non-compliance with the minimum bid price requirement of $1.00 for 30 consecutive trading days. The company is not eligible for the standard compliance period due to previous reverse stock splits.
Key developments:
- Company executed a reverse stock split on June 27, 2024
- Shareholders approved a new reverse split ratio of 1-for-5 to 1-for-70 at May 20, 2025 annual meeting
- Board intends to implement another reverse stock split to regain compliance
- Company plans to request a hearing with Nasdaq Hearings Panel
Stock will remain listed on Nasdaq Capital Market pending the hearing outcome. However, there is no guarantee of continued listing or successful compliance restoration. This situation presents significant risks for investors, including potential delisting and further share dilution through another reverse split.
FAQ
What is the current stock price of Nuwellis (NUWE)?
What is the market cap of Nuwellis (NUWE)?
What is the primary focus of Nuwellis Inc?
What are the core products offered by Nuwellis Inc?
How does the Aquadex SmartFlow System work?
What benefits does the RenalSense Clarity RMS provide?
How does Nuwellis Inc differentiate itself from competitors?
Who are the primary customers of Nuwellis Inc?
What is the clinical significance of Nuwellis Inc's technologies?
What kind of clinical evidence supports Nuwellis Inc's products?
